Department of Cardiac Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8560, Japan.
J Artif Organs. 2024 Sep;27(3):182-187. doi: 10.1007/s10047-024-01441-3. Epub 2024 Mar 29.
Heart transplantation is considered to be the best treatment for severe heart failure refractory to medical therapy, improving patients' survival and quality of life (QOL). However, the number of donors is smaller than the number of registered applicants for heart transplantation, which increases every year, and the waiting period for heart transplantation has been extended to more than 1700 days by 2022. Since 2011, reimbursement for the implantable left ventricular assist device (iLVAD) was established. The numbers of the iLVAD patients have been increasing year by year. Patients are managed at home with an iLVAD and can live with their families and even return to work, depending on the situation. On the other hand, self-management at home, including caregivers, is important for a safe life. Home management beyond 5 years is becoming more common due to long waiting time for transplant. This article outlines the important aspects of patient management for long-term support. This review was created based on a translation of the Japanese review written in the Japanese Journal of Artificial Organs in 2023 (Vol. 52, No. 1, pp. 62-66), with some modifications.
心脏移植被认为是治疗对药物治疗无效的严重心力衰竭的最佳方法，可以提高患者的生存率和生活质量（QOL）。然而，供体数量小于每年都在增加的注册心脏移植申请人的数量，到 2022 年，心脏移植的等待时间已经延长到 1700 多天。自 2011 年以来，植入式左心室辅助装置（iLVAD）的报销已经建立。iLVAD 患者的数量逐年增加。患者在家中使用 iLVAD 进行管理，根据情况，可以与家人一起生活，甚至可以重返工作岗位。另一方面，包括护理人员在内的在家中的自我管理对于安全的生活非常重要。由于等待移植的时间长，5 年以上的家庭管理变得越来越普遍。本文概述了长期支持患者管理的重要方面。本文是基于 2023 年《日本人工器官杂志》（第 52 卷，第 1 期，第 62-66 页）上发表的一篇日文综述的翻译，并做了一些修改。
